Jeanne M Marrazzo1, Lorna Rabe2, Cliff Kelly3,4, Barbra Richardson3,4, Carolyn Deal5, Jill L Schwartz6, Z M Chirenje7, Jeanna Piper8, Rhoda Ashley Morrow3,4, Craig W Hendrix9, Mark A Marzinke9, Sharon L Hillier2,10. 1. University of Alabama-Birmingham. 2. Magee-Womens Research Institute, Pittsburgh, Pennsylvania. 3. University of Washington, Seattle, Washington. 4. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 5. Division of Microbiology and Infectious Disease, Bethesda. 6. CONRAD/Eastern Virginia Medical School, Arlington. 7. University of Zimbabwe-University of California San Francisco Research Program, Harare, Zimbabwe. 8. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda. 9. Johns Hopkins University School of Medicine, Baltimore, Maryland. 10. University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Genital infection with herpes simplex virus type 2 (HSV-2) is common and increases risk of human immunodeficiency virus (HIV) transmission and acquisition. Pericoital use of tenofovir (TFV) gel provided protection from HSV-2 acquisition in the CAPRISA 004 study. METHODS: We measured estimate of effect of vaginal TFV 1% gel in preventing HSV-2 acquisition among women in VOICE, randomized, double-blinded, placebo-controlled trial assessing daily use of oral and vaginal TFV for HIV-1 preexposure prophylaxis. The TFV level in plasma at the first quarterly visit was used as a measure of gel use. RESULTS: Of 566 participants at risk for HSV-2 acquisition, 532 (94%) had first-quarter plasma TFV and end-of-study HSV-2 serologic data available. Over a follow-up period of 501 person-years, 92 incident cases of HSV-2 acquisition occurred: 77 were in women with no TFV detected in plasma, and 15 occurred in women with TFV detected in plasma (incidence, 20.6 cases/100 person-years [95% confidence interval [CI], 16.2-25.7] vs 11.9 cases/100 person-years [95% CI, 6.6-19.6], respectively). TFV detection in plasma was associated with a trend toward a reduced risk of HSV-2 seroconversion, with an unadjusted hazard ratio (HR) of 0.59 (95% CI, .34-1.02; P = .060) and a HR adjusted for site, age, having ≥2 male sex partners in the past 3 months, use of hormonal contraception, having anal sex in the past 3 months, and HIV status of 0.60 (95% CI, .33-1.08; P = .086). CONCLUSIONS: Detection of TFV in plasma among TFV gel users was associated with a trend toward a reduced risk of HSV-2 acquisition, after controlling for sexual behavior and HIV-1 acquisition.
RCT Entities:
BACKGROUND:Genital infection with herpes simplex virus type 2 (HSV-2) is common and increases risk of human immunodeficiency virus (HIV) transmission and acquisition. Pericoital use of tenofovir (TFV) gel provided protection from HSV-2 acquisition in the CAPRISA 004 study. METHODS: We measured estimate of effect of vaginal TFV 1% gel in preventing HSV-2 acquisition among women in VOICE, randomized, double-blinded, placebo-controlled trial assessing daily use of oral and vaginal TFV for HIV-1 preexposure prophylaxis. The TFV level in plasma at the first quarterly visit was used as a measure of gel use. RESULTS: Of 566 participants at risk for HSV-2 acquisition, 532 (94%) had first-quarter plasma TFV and end-of-study HSV-2 serologic data available. Over a follow-up period of 501 person-years, 92 incident cases of HSV-2 acquisition occurred: 77 were in women with no TFV detected in plasma, and 15 occurred in women with TFV detected in plasma (incidence, 20.6 cases/100 person-years [95% confidence interval [CI], 16.2-25.7] vs 11.9 cases/100 person-years [95% CI, 6.6-19.6], respectively). TFV detection in plasma was associated with a trend toward a reduced risk of HSV-2 seroconversion, with an unadjusted hazard ratio (HR) of 0.59 (95% CI, .34-1.02; P = .060) and a HR adjusted for site, age, having ≥2 male sex partners in the past 3 months, use of hormonal contraception, having anal sex in the past 3 months, and HIV status of 0.60 (95% CI, .33-1.08; P = .086). CONCLUSIONS: Detection of TFV in plasma among TFV gel users was associated with a trend toward a reduced risk of HSV-2 acquisition, after controlling for sexual behavior and HIV-1 acquisition.
Authors: Graciela Andrei; Andrea Lisco; Christophe Vanpouille; Andrea Introini; Emanuela Balestra; Joost van den Oord; Tomas Cihlar; Carlo-Federico Perno; Robert Snoeck; Leonid Margolis; Jan Balzarini Journal: Cell Host Microbe Date: 2011-10-20 Impact factor: 21.023
Authors: James Y Dai; Craig W Hendrix; Barbra A Richardson; Cliff Kelly; Mark Marzinke; Z Mike Chirenje; Jeanne M Marrazzo; Elizabeth R Brown Journal: J Infect Dis Date: 2015-06-29 Impact factor: 5.226
Authors: Christine Johnston; Misty Saracino; Steve Kuntz; Amalia Magaret; Stacy Selke; Meei-Li Huang; Joshua T Schiffer; David M Koelle; Lawrence Corey; Anna Wald Journal: Lancet Date: 2012-01-04 Impact factor: 79.321
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Jill L Schwartz; Wes Rountree; Angela D M Kashuba; Vivian Brache; Mitchell D Creinin; Alfred Poindexter; Brian P Kearney Journal: PLoS One Date: 2011-10-19 Impact factor: 3.240
Authors: John Bradley; Sian Floyd; Estelle Piwowar-Manning; Oliver Laeyendecker; Alicia Young; Nomtha Bell-Mandla; Justin Bwalya; Peter Bock; Sarah Fidler; Helen Ayles; Richard J Hayes Journal: J Infect Dis Date: 2018-07-02 Impact factor: 5.226
Authors: Dvora L Joseph Davey; Linda-Gail Bekker; Elizabeth A Bukusi; Benjamin H Chi; Sinead Delany-Moretlwe; Ameena Goga; Anne Drapkin Lyerly; Nyaradzo M Mgodi; Nelly Mugo; Landon Myer; Lisa M Noguchi; Lynda Stranix-Chibanda; Catherine Slack; Jillian Pintye Journal: Lancet HIV Date: 2022-01-25 Impact factor: 16.070
Authors: Tajanna Stinn; Steve Kuntz; Dana Varon; Meei-Li Huang; Stacy Selke; Samuel Njikan; Emily S Ford; Joan Dragavon; Robert W Coombs; Christine Johnston; Marta E Bull Journal: J Virol Date: 2020-12-09 Impact factor: 5.103
Authors: Gui Liu; Nelly R Mugo; Elizabeth R Brown; Nyaradzo M Mgodi; Zvavahera M Chirenje; Jeanne M Marrazzo; Rachel L Winer; Leila Mansoor; Thesla Palanee-Phillips; Samantha S Siva; Logashvari Naidoo; Nitesha Jeenarain; Zakir Gaffoor; Gonasagrie L Nair; Pearl Selepe; Clemensia Nakabiito; Baningi Mkhize; Brenda Gati Mirembe; Marthinette Taljaard; Ravindre Panchia; Jared M Baeten; Jennifer E Balkus; Florian Hladik; Connie L Celum; Ruanne V Barnabas Journal: AIDS Date: 2022-02-01 Impact factor: 4.632